Page last updated: 2024-11-13
ck-2017357
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CK-2017357: a fast-skeletal-troponin activator; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 23729157 |
CHEMBL ID | 3039529 |
SCHEMBL ID | 976988 |
MeSH ID | M0574411 |
Synonyms (46)
Synonym |
---|
tirasemtiv |
ck-2017357 |
bdbm50316148 |
D10327 |
tirasemtiv (usan/inn) |
CHEMBL3039529 |
2h-imidazo(4,5-b)pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro- |
6-ethynyl-1-(pentan-3-yl)-2h-imidazo(4,5-b)pyrazin-2-one |
1005491-05-3 |
1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-2h-imidazo(4,5-b)pyrazin-2-one |
unii-g8wsm7r635 |
tirasemtiv [usan:inn] |
ck2017357 |
g8wsm7r635 , |
ck 2017357 |
tirasemtiv [who-dd] |
tirasemtiv [inn] |
tirasemtiv [usan] |
RSQGZEAXODVTOL-UHFFFAOYSA-N |
6-ethynyl-1-(pentan-3-yl)-1h-imidazo[4,5-b]pyrazin-2-ol |
HY-15964 |
SCHEMBL976988 |
tirasemtiv(ck-2017357) |
5-ethynyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one |
tirasemtiv (ck-2017357) |
gtpl8280 |
DTXSID90143379 |
EX-A367 |
AKOS027250724 |
mfcd28023588 |
NCGC00378555-02 |
2h-imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-;2h-imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro- |
DB12209 |
FT-0746303 |
6-ethynyl-1-(pentan-3-yl)-1,3-dihydro-2h-imidazo[4,5-b]pyrazin-2-one |
Q27088998 |
BCP27991 |
ck2017357; ck-2017357; ck 2017357 |
S0196 |
SB16955 |
1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-2h-imidazo[4,5-b]pyrazin-2-one |
W97 , |
A898831 |
6-ethynyl-1-(pentan-3-yl)-1h-imidazo[4,5-b]pyrazin-2(3h)-one |
AC-35962 |
BS-22417 |
Research Excerpts
Toxicity
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
"This study was designed to evaluate the safety and tolerability of single doses of CK-2017357, an orally bioavailable fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis (ALS), and to explore pharmacodynamic markers related to strength, endurance, and function." | ( Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Cedarbaum, JM; Chen, M; Cudkowicz, ME; Hansen, RL; Jones, D; Lee, J; Mahoney, K; Malik, F; Mao, J; Maragakis, N; Russell, AJ; Saikali, K; Shefner, J; Watson, ML; Wolff, AA, 2012) | 0.6 |
Bioavailability
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Sixty-three patients completed all three dosing periods." | ( Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Cedarbaum, JM; Chen, M; Cudkowicz, ME; Hansen, RL; Jones, D; Lee, J; Mahoney, K; Malik, F; Mao, J; Maragakis, N; Russell, AJ; Saikali, K; Shefner, J; Watson, ML; Wolff, AA, 2012) | 0.38 |
" Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting 28 days." | ( A phase III trial of Andrews, JA; Cockcroft, BM; Cudkowicz, ME; Hardiman, O; Lee, JH; Malik, FI; Meng, L; Rudnicki, SA; Shefner, JM; Wolff, AA, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 5.3547 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
G | Vesicular stomatitis virus | Potency | 8.4866 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2D6 | Homo sapiens (human) | Potency | 26.8370 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
Interferon beta | Homo sapiens (human) | Potency | 8.4866 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 8.4866 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 8.4866 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 8.4866 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (45)
Molecular Functions (18)
Ceullar Components (22)
Bioassays (34)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1785408 | Drug distribution in Sprague-Dawley rat Soleus muscle to blood ratio at 100 mg/kg, po by HPLC analysis | 2021 | Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20 | Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. |
AID1354435 | Ratio of IC50 for CYP1A2 in human liver microsomes to IC50 for CYP1A2 in human liver microsomes preincubated for 20 mins with compound | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1785411 | Efflux ratio of apparent permeability in human Caco-2 cells | 2021 | Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20 | Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. |
AID1354431 | Oral bioavailability in mouse at 1 mg/kg by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354417 | Extraction ratio in human liver microsomes measured up to 90 mins by HPLC/MS/MS analysis | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354418 | Clearance in Sprague-Dawley rat at 1 mg/kg, po or 1 mg/kg iv via bolus by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354419 | Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, po or 1 mg/kg iv via bolus by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1785406 | Plasma protein binding in male rat assessed as unbound fraction | 2021 | Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20 | Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. |
AID1354433 | Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate in presence of NADP | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354427 | Clearance in mouse at 1 mg/kg, po or 1 mg/kg iv via bolus by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354412 | Activation of troponin in rabbit fast skeletal muscle fibers assessed as increase in calcium stimulated activity by measuring compound concentration that produces 40% increase in myofibril ATPase activity at 25% of calcium concentration needed for maximal | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354432 | Apparent permeability of the compound in human Caco2 cells | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354429 | Volume of distribution at steady state in mouse at 1 mg/kg, po or 1 mg/kg iv via bolus by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354434 | Time dependent inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate preincubated for 20 mins followed by NADP addition | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354421 | Fraction unbound in rat plasma at 5 uM after 6 hrs by equilibrium dialysis based HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354420 | Oral bioavailability in Sprague-Dawley rat at 1 mg/kg by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1785407 | Drug distribution in Sprague-Dawley rat brain to blood ratio at 100 mg/kg, po by HPLC analysis | 2021 | Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20 | Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. |
AID1354416 | Extraction ratio in rat liver microsomes measured up to 90 mins by HPLC/MS/MS analysis | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354425 | Extraction ratio in mouse liver microsomes measured up to 90 mins by HPLC/MS/MS analysis | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354422 | Fraction unbound in human plasma at 5 uM after 6 hrs by equilibrium dialysis based HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354428 | Volume of distribution at steady state in Beagle dog at 1 mg/kg, po or 1 mg/kg iv via bolus by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354415 | Activation of troponin in rabbit fast skeletal muscle fibers assessed as increase in calcium stimulated activity by measuring compound concentration that produces 30% increase in tension at 25% of calcium concentration needed for maximal response by pyruv | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354423 | Increase in muscle force in rat extensor digitorum longus muscle dosed systemically measured every two mins by in situ live fiber activity assay | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354430 | Oral bioavailability in Beagle dog at 1 mg/kg by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1785405 | Increase in muscle tension in rat extensor digitorum longus muscle rat model assessed as free plasma concentration to increase muscle tension at subtetanic nerve stimulation rate of 30 Hz | 2021 | Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20 | Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. |
AID1354424 | Extraction ratio in dog liver microsomes measured up to 90 mins by HPLC/MS/MS analysis | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1354426 | Clearance in Beagle dog at 1 mg/kg, po or 1 mg/kg iv via bolus by HPLC method | 2018 | ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4 | Discovery of |
AID1785410 | Drug distribution in Sprague-Dawley rat plasma to blood ratio at 100 mg/kg, po by HPLC analysis | 2021 | Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20 | Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. |
AID1785409 | Drug distribution in Sprague-Dawley rat extensor digitorum longus to blood ratio at 100 mg/kg, po by HPLC analysis | 2021 | Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20 | Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 16 (72.73) | 24.3611 |
2020's | 6 (27.27) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 16.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.30) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 8 (34.78%) | 5.53% |
Reviews | 2 (8.70%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (56.52%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |